Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic.
Publication
, Journal Article
Middleton, JP; Wolf, M
Published in: JAMA
January 10, 2017
Duke Scholars
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
January 10, 2017
Volume
317
Issue
2
Start / End Page
139 / 141
Location
United States
Related Subject Headings
- Kidney Failure, Chronic
- Hyperparathyroidism, Secondary
- Humans
- General & Internal Medicine
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Middleton, J. P., & Wolf, M. (2017). Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic. JAMA, 317(2), 139–141. https://doi.org/10.1001/jama.2016.18631
Middleton, John P., and Myles Wolf. “Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic.” JAMA 317, no. 2 (January 10, 2017): 139–41. https://doi.org/10.1001/jama.2016.18631.
Middleton JP, Wolf M. Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic. JAMA. 2017 Jan 10;317(2):139–41.
Middleton, John P., and Myles Wolf. “Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic.” JAMA, vol. 317, no. 2, Jan. 2017, pp. 139–41. Pubmed, doi:10.1001/jama.2016.18631.
Middleton JP, Wolf M. Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic. JAMA. 2017 Jan 10;317(2):139–141.
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
January 10, 2017
Volume
317
Issue
2
Start / End Page
139 / 141
Location
United States
Related Subject Headings
- Kidney Failure, Chronic
- Hyperparathyroidism, Secondary
- Humans
- General & Internal Medicine
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences